Pipeline

We are working to deliver best-in-class pan-variant tyrosine kinase inhibitors (TKIs) to fight cancer.

Our pipeline focuses on developing next-generation TKIs that address treatment resistance in cancer.
Program/Target
Indication Stage
Discovery
IND-Enabling
Phase 1
Phase 2
Phase 3
Worldwide Rights
THE-630/KIT GIST
GIST Phase 1
THE-349/EGFR NSCLC
NSCLC IND-Enabling
BCR-ABL CML,
Ph+ ALL
CML,
Ph+ ALL Discovery
We are targeting cancers where current therapies are limited by the burden of treatment resistance.

LEARN ABOUT OUR DISEASE FOCUS